NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Attovia Therapeutics, Inc. (ATTO) Stock Analysis

Attovia Therapeutics, Inc. (ATTO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ATTO

$25.55

+$1.35 (+5.58%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATTO with… →

ATTO Key Statistics

As of Sep 4, 2026
Trading
Open
$24.44
Previous Close
$24.20
Day's Range
24.44–27.66
52-Week Range
16.15–27.66
Volume
311.00K
Valuation
Market Cap
$1.17B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
863.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.63
Financials (FY)
Revenue (FY)
$1.35M
Net Income (FY)
−$60.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.65M
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
470.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ATTO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.35M−$60.63M−4490.9%
2024$0.00−$39.80M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.35M—−$67.16M−$60.63M−4490.9%
2024$0.00—−$41.55M−$39.80M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATTO Valuation vs Biotechnology Median

Median of 656 stocks
MetricATTOBiotechnology medianvs median
P/S ratio863.9915.2656.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Attovia Therapeutics, Inc. (ATTO) is capitalised at $1.17B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 44 employees.

The 52-week range on file runs from $16.15 to $27.66. The most recent close on file for ATTO is $25.55, dated September 4, 2026. That is +$1.35 (+5.58%) against the previous close. The latest close sits 58.2% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.35M. The same year closed with a net loss of $60.63M. The reported profit margin is 0%. Trailing earnings per share are −1.63.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 863.99. On price-to-sales that is 56.6 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Growth & Income

The record shows no dividend for ATTO.

So far in 2026 the price is +16.67%.

Peer Comparison

Attovia Therapeutics, Inc. (ATTO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Attovia Therapeutics, Inc. ATTO $1.17B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Attovia Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.

Visit website →